This article is more than 5 years old. Information may no longer be current.

EyeGate earns milestone payment based on EGP-437 trial enrollment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals announced it reached 75% enrollment in a pivotal phase 3 clinical trial of EGP-437 for the treatment of noninfectious anterior uveitis.

The double-masked, randomized, positive-controlled trial is designed to assess the safety and efficacy of iontophoretically delivered EGP-437. The trial will enroll 250 subjects in the U.S., according to a company press release.

By achieving 75% enrollment in the trial, EyeGate earned a milestone payment under a licensing agreement with a subsidiary of Valeant Pharmaceuticals.

EGP-437 is a novel formulation of dexamethasone phosphate ophthalmic solution, delivered by the EyeGate II delivery system. The delivery system may eliminate the need for frequently administered topical steroids over multiple weeks.

Topline date from the trial are expected to be released in the second quarter of 2018.

Barbara Wirostko, MD, chief medical officer of EyeGate, said in the release the company expects to file a new drug application for EGP-437 for anterior uveitis in 2018.